bioRxivEvolutionary Biology
Diversity and Evolution of Computationally Predicted T Cell Epitopes against Human Respiratory Syncytial Virus
J. Chen, S. Tan, V. Avadhanula, L. Moise, P. A. Piedra, A. S. De Groot, J. Bahl
Abstract
Human respiratory syncytial virus (RSV) is a major cause of lower respiratory infection. Despite more than 60 years of research, there is no licensed vaccine. While B cell response is a major focus for vaccine design, the T cell epitope profile of RSV is also important for vaccine development. Here, we computationally predicted putative T cell epitopes in the Fusion protein (F) and Glycoprotein (G) of RSV wild circulating strains by predicting Major Histocompatibility Complex (MHC) class I and class II binding affinity. We limited our inferences to conserved epitopes in both F and G proteins that have been experimentally validated. We applied multidimensional scaling (MDS) to construct T cell epitope landscapes to investigate the diversity and evolution of T cell profiles across different RSV strains. We find the RSV strains are clustered into three RSV-A groups and two RSV-B groups on this T epitope landscape. These clusters represent divergent RSV strains with potentially different immunogenic profiles. In addition, our results show a greater proportion of F protein T cell epitope content conservation among recent epidemic strains, whereas the G protein T cell epitope content was decreased. Importantly, our results suggest that RSV-A and RSV-B have different patterns of epitope drift and replacement and that RSV-B vaccines may need more frequent updates. Our study provides a novel framework to study RSV T cell epitope evolution. Understanding the patterns of T cell epitope conservation and change may be valuable for vaccine design and assessment. Author SummaryLower respiratory infections caused by human respiratory syncytial virus (RSV) is a global health challenge. B cell epitope immune response has been the major focus of RSV vaccine and therapeutic development. However, T cell epitope induced immunity plays an important role in the resolution of RSV infection. While RSV genetic diversity has been widely reported, few studies focus on RSV T epitope diversity, which can influence vaccine effectiveness. Here, we use computationally predicted T cell epitope profiles of circulating strains to characterize the diversity and evolution of the T cell epitope of RSV A and B. We systematically evaluate the T epitope profile of RSV F and G proteins. We provide a T cell epitope landscape visualization that shows co-circulation of three RSV-A groups and two RSV-B groups, suggesting potentially distinct T cell immunity. Furthermore, our study shows different levels of F and G protein T cell epitope content conservation, which may be important to correlate with duration of vaccine protection. This study provides a novel framework to study RSV T cell epitope evolution, infer RSV T cell immunity at population levels and monitor RSV vaccine effectiveness.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Exploring different virulent proteins of human respiratory syncytial virus for designing a novel epitope-based polyvalent vaccine: Immunoinformatics and molecular dynamics approaches
A. T. Moin, M. A. Ullah, … S. Islam·bioRxiv·Feb 2, 2022
- Flexible RSV prefusogenic fusion glycoprotein exposes multiple neutralizing epitopes that may collectively contribute to protective immunity
N. Natel, J.-H. Tian, … G. Smith·bioRxiv·Sep 14, 2020
- A hierarchical activation threshold shapes RSV F antibody repertoires from toddler vulnerability to adult protection
Jie Deng, Yixin Li, … Xiangxi Wang·bioRxiv·Jul 29, 2026
- A rhinovirus vaccine evokes T cell mediated cross-reactive immunity in a preclinical model of rhinovirus infection
Stephen Michael Shaw, Chloe Julia Pyle, … Sebastian Lennox Johnston·bioRxiv·Jan 7, 2026
- Development and validation of a respiratory syncytial virus multiplex immunoassay
P. Marsall, M. Fandrich, … A. Dulovic·InfectionPeer-reviewed·Feb 8, 2024
- A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein
J. Huang, R. Miller, J. J. Mousa·bioRxiv·Feb 24, 2022